CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile.
Trivedi
B K
BK
Department of Medicinal Chemistry, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.
Hinton
J P
JP
D000218:Adamantane / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000284:Administration, Oral; D000818:Animals; D001921:Brain / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics; D008536:Meglumine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D014364:Tryptophan / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D007211:Indoles; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C065599:PD 134308; D008536:Meglumine; C110350:CI 1015; D014364:Tryptophan; D000218:Adamantane